The gene therapy unit of Amicus Therapeutics, a public American biopharmaceutical company, is set to go public via merger with ARYA Sciences Acquisition IV, a special purpose acquisition company backed by Perceptive Advisors, in a $600m deal. "This is a big, bold vision and a massive step forward for next generation biotechnologies for people worldwide living with some of the most devastating rare diseases. In a single stroke with the formation and funding of Caritas we will create what will be one of the world’s preeminent next-generation genetic medicines companies. We strongly believe that separating our business into two highly focused, stand-alone companies is the best way to unlock significant value for Amicus shareholders and to advance our medicines and technologies to people living with rare diseases around the world," John F. Crowley, Amicus Chairman and CEO.